ArticleCureus2026
Clinical Outcomes Following Definitive Concurrent Chemoradiotherapy in Patients With International Federation of Gynecology and Obstetrics (FIGO) Stage IB-IVA Carcinoma of the Cervix.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim Cervical malignancy among women is associated with substantial mortality and morbidity. This study aimed to determine the clinical outcomes of definitive concurrent chemoradiotherapy (CCRT) in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IVA cervical carcinoma. Methods This was a prospective, single-arm, interventional (experimental) study. Patients with cervical carcinoma fulfilling the inclusion criteria were planned for CCRT with weekly cisplatin injections (40 mg/m²). Patients with biopsy-proven squamous cell or adenosquamous carcinoma of the cervix, aged 25-65 years, with node-negative (N0) or node-positive (N1) nonmetastatic (M0) disease were included. However, patients with multiple comorbidities, Eastern Cooperative Oncology Group performance status III/IV, previous treatment for cervical cancer, or a history of any other malignancy were excluded. Treatment planning for all patients was performed using a conventional 2D simulator, and patients were treated with 45 Gy external beam radiotherapy (RT) in 25 fractions. A parametrial boost was given after 45 Gy, up to 60 Gy, in patients with parametrial involvement. Data were analyzed using IBM SPSS Statistics for Windows, version 25.0 (released 2017; IBM Corp., Armonk, NY, USA), and the Fisher-Freeman-Halton exact test was applied to compare response rates among patients with different pretreatment FIGO stages. Fisher's exact test was used to compare response rates after treatment among different histological types. A p-value ≤0.05 was considered significant. Results Complete response was observed in 53 (42.7%) patients, while partial response was seen in 45 (36.2%) patients. Stable disease was present in 17 (13.8%) patients, while progressive disease was seen in nine (7.3%) patients. There was a significant difference in response rate across different pretreatment FIGO stages. In our clinical setting, routine human papillomavirus screening and vaccination are not uniformly implemented because of limited resources, inadequate organized screening programs, low public awareness, and financial constraints. This study evaluated the clinical outcomes of definitive CCRT in patients with cervical carcinoma in our population. Conclusions Radical CCRT with weekly cisplatin demonstrated favorable short-term treatment outcomes in patients with FIGO stage IB-IVA cervical carcinoma. Most patients achieved a favorable treatment response, supporting acceptable locoregional disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.